Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. International Most cancers Statistics 2020: GLOBOCAN estimates of incidence...
ORIC-944, a possible best-in-class PRC2 inhibitor, is being evaluated together with darolutamide and together with apalutamide in sufferers with mCRPC ...